The marketing authorisation was granted following a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) European…
In recent years, the inclusion of immunotherapy in the therapeutic algorithm of patients with PD-L1-positive advanced head and neck cancer…
SEIMC-GeSIDA Foundation and ViiV Healthcare announced positive 48-week results from the Paso Doble study (GeSIDA study 11720), the largest randomized…